• Zura Bio (ZURA) is the clearest speculative opportunity mentioned: the speaker sees potential upside from about $3 to $10, but offered no supporting valuation or timeframe, so treat the target cautiously.
• Ultragenyx (RARE) was also viewed favorably, with the speaker suggesting it could double based on its rare-disease pipeline and revenue; no timeframe was given, and heavy R&D spending remains a risk.
• Avoid treating steep declines as automatic bargains: the speaker would not touch Brazilian equities, including EWZ, amid election, currency, and regulatory uncertainty.
• The speaker is skeptical of the Anthropic IPO unless investors can assess management and offering valuation, and highlighted unresolved compute costs and future obligations.

Anthropic (private; IPO discussed)

• The speaker reviewed what he described as Anthropic’s S-1. The filing listed customer testimonials from companies including AIG, Bristol Myers Squibb, and DoorDash; he also noted 5,300 employees and a small board.
• He cited revenue of $41 million in 2023, $386 million the following year, and $5 billion last year. He speculated that revenue could reach $40–50 billion this year; that was an estimate, not a reported result.
• He said the company had positive cash flow in the first half of 2026, but noted that this apparently excluded capital spending. He questioned the company’s roughly $1 billion in property, plant, and equipment, given its compute needs, and said much of the compute appeared to be held off balance sheet. The transcript also cites $417 billion in minimum future obligations, though the speaker found the vendor relationships and accounting complex.
• He discussed large increases in private share prices across funding rounds, but said he was still unsure how preferred shares would convert and whether his cap-table calculations were right.
• His view of the IPO was cautious: “I don’t think the Anthropic IPO is a good opportunity” unless an investor has a strong understanding of the management team and the offering price. He questioned whether AI companies can retain users and monetize their products over the long term, while acknowledging Anthropic’s rapid revenue growth and reported cash generation.

Takeaways

• Treat the revenue-growth figures and cap-table math as uncertain where the speaker was estimating or explicitly unsure.
• The main investment questions raised were IPO valuation, management quality, returns on capital, compute spending, off-balance-sheet obligations, and customer retention.
• The speaker’s comments were not a recommendation to buy the IPO; he was expressly skeptical without a clearer view of management and price.

Brazil and Brazilian equities (EWZ, PBR, NU, MELI, VALE)

• The speaker described Brazil’s election as contested and questioned its legitimacy, while acknowledging he was not an expert on the situation.
• The iShares MSCI Brazil ETF (EWZ) fell roughly 24–26%, with the speaker calling the move the largest single-day plunge in its history. It later rallied about 1% but remained sharply lower. He said Brazil seemed oversold, but also said he would not touch Brazilian equities.
• He noted declines in Petrobras (PBR), down about 15%; Nu Holdings (NU), down about 22%; and MercadoLibre (MELI), down about 12%. He also mentioned Vale (VALE) in a discussion of Brazilian stocks, but did not offer a specific view on it.
• His broader warning was that emerging-market investing can involve extreme moves from currency and political risk. He said markets can fall 50–90% and described local-market investing as potentially difficult because of unfamiliar regulations, currency exposure, and legal processes.

Takeaways

• The discussion was cautious to bearish on Brazilian stocks despite the suggestion that EWZ might be oversold.
• The risks specifically raised were election uncertainty, currency volatility, political and regulatory surprises, and the possibility of very large drawdowns.
• The speaker’s practical stance was to stay within areas an investor understands rather than treat a steep decline alone as a buy signal.

Moderna (MRNA) and Merck (MRK)

• The speaker said Moderna had patient deaths in a trial and initially fell about 4%, later reaching a decline of roughly 8%, before recovering and trading higher. He was surprised the stock held up and said he would stop shorting Moderna, adding that the trial data was “not that great” but that the share-price reaction did not support the short thesis at that moment.
• The guest compared Moderna’s prospects with Merck, discussing a cancer-treatment combination with a cited 42% efficacy figure. The speaker said the treatment appeared useful and could sell well, particularly in an adjuvant setting—after a tumor has been removed—where patients may take treatment for a longer period.
• The discussion distinguished this setting from metastatic cancer, where the speaker said treatment may be used for a shorter period and outcomes are worse.

Takeaways

• Sentiment on Moderna was mixed: concern about trial news, but caution against maintaining a short position after the stock recovered.
• The guest raised Merck as a possible stronger competitor, while the speaker emphasized the commercial appeal of longer-duration adjuvant treatment.
• The transcript did not provide a price target or a specific buy recommendation for either company.

Nebius (NBIS) and CoreWeave (CRWV)

• The speaker noted Nebius was down about 5% and referred to CoreWeave falling to around $52 before later mentioning a gap higher. He discussed Elon Musk’s warning that other cloud companies might not have financing and wondered whether Musk had an interest in disrupting financing for companies such as Nebius and CoreWeave.
• He also raised concern about possible GPU overcapacity and called the “neo-cloud” business model flawed, while acknowledging that someone needs to provide this infrastructure.
• On CoreWeave, he said the key question for shareholders was how much value would remain for equity holders, rather than simply how much financing the company could obtain.

Takeaways

• The discussion highlighted financing access, GPU overcapacity, business-model durability, and dilution or debt burdens as key risks for AI-cloud infrastructure companies.
• The speaker’s comments were questioning rather than a clear endorsement or recommendation.

IonQ (IONQ) and quantum computing

• The speaker said quantum stocks were taking a hit and called IonQ “trash” and overvalued at $30.

Takeaways

• The sentiment was bearish on IonQ at the cited price.
• The transcript provided no valuation analysis beyond that opinion and no price target.

SELLAS Life Sciences (SLS)

• The speaker told a viewer to get out of SLS, saying the position could materially reduce the account’s Sharpe ratio. He also said an account he had reviewed remained heavily invested in the stock, possibly around half of its portfolio.

Takeaways

• The speaker’s view was strongly bearish, and his direct advice to the viewer was to exit.
• This was a specific opinion addressed to a viewer; the transcript did not provide further analysis of SLS’s business or valuation.

Humacyte (HUMA)

• The guest said she remained long Humacyte, whose ATEV product is intended to provide vascular access for hemodialysis patients. She cited interim Phase 3 results and said the product could provide functional access sooner and reduce time using dialysis catheters.
• The guest said the number of hospitals increased from 34 to 49, a 44% increase. The speaker noted reported quarterly revenue of about $400,000, compared with $100,000 in the prior quarter.
• The speaker was highly skeptical. He said, in his view, the trial had not shown the product was better than a plastic-vein alternative, questioned whether hospitals were adopting it, and speculated that distributors might be buying product without strong end demand. He also said the company had not reported the proposed $1.7 million Saudi investment mentioned by the guest.
• The guest said the product’s shelf life had been extended. The speaker remained concerned that the company’s reported sales were too small to demonstrate meaningful commercial demand.

Takeaways

• The discussion presented a sharp split: the guest was bullish, while the speaker was strongly bearish on Humacyte’s commercial prospects.
• The key issues raised were hospital adoption, actual end-user demand, revenue growth, trial results, and whether the product is meaningfully better than existing alternatives.
• The guest’s long position and the speaker’s skepticism are opinions from the discussion, not a settled conclusion about the company.

OraSure Technologies (OSUR)

• The guest described OraSure as a possible play on demand for Ebola test kits, including potential demand in Europe. The speaker called it a diagnostics company rather than a biotech drug company, questioned how large the Ebola-testing market could be, and suggested the guest consider moving on.
• The speaker cited a market capitalization of about $300 million. The guest said she planned to hold through earnings, but the conversation did not establish a specific revenue forecast or confirmed Ebola-related sales.

Takeaways

• Sentiment was skeptical from the speaker and speculative from the guest.
• The main question raised was whether potential test-kit demand could become large and reliable enough to support the investment thesis.

Zura Bio (ZURA)

• The speaker identified Zura as a biotech he liked and said he thought the stock could rise from around $3 to $10.

Takeaways

• The speaker expressed a bullish view and gave a specific potential price target of $10.
• The transcript did not explain the valuation or catalysts behind that target, so treat it as an opinion rather than a fully developed investment case.

Ultragenyx Pharmaceutical (RARE)

• The speaker said he liked Ultragenyx and thought it could potentially double. He described the company as having substantial revenue and a broad rare-disease pipeline, and praised its founder’s experience in rare-disease drug development.
• He also said the company spends heavily on research and development and has pursued some projects he considered unnecessary or unsuccessful. He noted that some investors criticize the company for developing weaker drugs, while arguing that drug development involves taking risks.

Takeaways

• The speaker was bullish, citing its rare-disease expertise, revenue, and pipeline, while also flagging R&D spending and uneven project outcomes.
• The potential to double was the speaker’s stated view; the transcript did not provide a timeframe or a price target.

Xeris Biopharma (XERS)

• The speaker said Xeris had revenue and a pipeline and compared it loosely with a company he had previously started, describing it as “not such a bad thing.”
• The discussion mentioned treatments associated with Cushing’s syndrome and hypercortisolemia, but did not provide detailed product, sales, or valuation analysis.

Takeaways

• The speaker’s tone was mildly constructive, but the discussion did not amount to a specific recommendation.
• Further assessment would require understanding the company’s products, revenue, and pipeline prospects; those details were not explored in the transcript.

Netlist (NLST)

• The guest described Netlist as a memory-related company with patent licenses and resale operations. She cited a $200 million upfront Samsung payment, followed by $28–34 million per quarter for 20 quarters, as well as a separate Micron patent settlement. She also mentioned a prior SK Hynix license that had not been renewed.
• The guest said Netlist had reported quarterly revenue of roughly $104 million and $109 million, with most of the first-quarter figure coming from reselling memory products.
• The speaker was skeptical about the business model and questioned whether Netlist actually manufactures products or mainly resells components. He also questioned whether the licensing settlements justified a roughly $2 billion market capitalization, and asked what further catalysts remained.

Takeaways

• The guest’s view was bullish, based on licensing payments and memory demand; the speaker was skeptical about the company’s operating model and valuation.
• The key issues raised were reliance on reselling, the durability of licensing revenue, manufacturing capabilities, and whether future cash generation supports the valuation.
• The transcript did not provide a clear earnings forecast or a firm conclusion on the company’s worth.

AXT, Inc. (AXTI)

• The guest called AXT her prior “100x” idea and said she had not owned enough of it. She cited the importance of indium phosphide (InP) substrates and said China-related restrictions had held the company back.

Takeaways

• The guest’s comments were bullish in hindsight, but she did not give a current price target or a fresh recommendation.
• The discussion pointed to InP substrate demand and China-related constraints as factors she considered important.

IQE plc (IQE; IQEPF)

• The guest described IQE as a supplier of epitaxial wafers used in semiconductor manufacturing. She cited its North Carolina factory, an investment from MACOM, and the retention of its Taiwan asset as reasons she was interested. She also referred to a U.S. investment announcement of $1.5 billion in North Carolina semiconductors.
• The speaker did not offer a substantive assessment of IQE.

Takeaways

• The guest’s thesis was bullish, tied to semiconductor supply-chain investment and wafer demand.
• The transcript did not give a target price, financial forecasts, or a detailed assessment of IQE’s business risks.

Butterfly Network (BFLY)

• The guest said Butterfly Network makes portable ultrasound devices and also developed a chip. She had previously traded the stock from about $1 to $7, was no longer holding it, and was considering it again as it returned toward its prior range.
• The speaker challenged the idea that it was meaningfully both a biotech and semiconductor company, and questioned the substance of the investment story.

Takeaways

• The guest was considering a possible re-entry, while the speaker was skeptical.
• The transcript did not provide current valuation analysis, business results, or a clear recommendation.

Semiconductor and memory themes (NVDA, TSM, LRCX, MU)

• The guest said she held NVIDIA (NVDA) exposure through a semiconductor ETF, but did not specify the ETF’s ticker.
• In a discussion of 13F filings, the speaker noted holdings in Taiwan Semiconductor (TSM), Lam Research (LRCX), and Micron (MU). These were examples from an institutional portfolio, not direct recommendations.
• The speaker said he was unsure about the memory-technology roadmap, mentioning 3D memory and newer technologies, and cautioned that it would take substantial research to assess the field.

Takeaways

• The transcript points to semiconductor exposure as an investment theme, but offers no specific recommendation on these individual stocks.
• The speaker’s main caution was not to rely on others’ holdings or opinions without understanding the underlying business and technology.

Hydrogen and fuel-cell investments (BE, PLUG, FCEL; HYDR discussed)

• The guest said she liked the Global X Hydrogen ETF (HYDR) as a way to gain exposure to hydrogen-related companies. She cited Bloom Energy (BE), Plug Power (PLUG), and FuelCell Energy (FCEL) as holdings or related bets in the fund.
• The speaker asked whether Bloom Energy was involved in hydrogen but did not offer a developed view on the company or the sector.

Takeaways

• The guest’s approach was to use an ETF rather than hold Bloom Energy directly; her comments were positive but not supported with a valuation case.
• The transcript did not discuss the underlying companies’ financial risks, and the speaker did not endorse the theme.

Bitcoin (BTC) and tokenized assets

• The speaker said he did not like crypto, describing it as backed by nothing. He speculated—without presenting evidence—that Jeffrey Epstein may have been involved in Bitcoin’s origins.
• Separately, he said he thought tokenized assets could become important, and mentioned Hyperliquid and other platforms as examples of activity in that area.

Takeaways

• The speaker was bearish on crypto broadly but more open to the idea of tokenizing conventional assets.
• His comments did not amount to a recommendation to buy Bitcoin, Hyperliquid, or any specific tokenized asset.

SpaceX, Rocket Lab (RKLB), and Palantir (PLTR)

• The guest said she regretted not putting money into Rocket Lab and Palantir in 2024, and described herself as a Rocket Lab investor.
• She said she thought SpaceX was a strong company but was concerned that it could have difficulty if Elon Musk were no longer involved. The speaker described this as key-person risk.
• SpaceX is private, and no specific investment terms or target were discussed.

Takeaways

• The guest’s comments were favorable toward Rocket Lab and SpaceX, and expressed hindsight regret about Palantir.
• The risk specifically discussed for SpaceX was dependence on a prominent founder; the transcript did not provide a current valuation view for these companies.

Nautilus (NAUT)

• The speaker called Nautilus a “fraud” and a “scam” during a discussion of biotech ideas. No supporting analysis was provided in the transcript.

Takeaways

• The speaker’s sentiment was strongly negative, but his claim was not substantiated in the discussion.
• Treat it as an unelaborated opinion, not as established fact.

Other brief stock and portfolio mentions

• IonQ (IONQ), Tesla (TSLA), Verizon (VZ), MakeMyTrip (MMYT), and Cadence Design Systems (CDNS) were mentioned in market updates or earnings-calendar discussion without detailed investment analysis.
• The speaker discussed using institutional 13F filings to find companies for further research. Examples included holdings in Amazon (AMZN), Alphabet (GOOGL), CRH, Telephone and Data Systems (TDS), Keysight Technologies (KEYS), Live Nation (LYV), Capital One (COF), and Hut 8 (HUT).
• He specifically warned viewers not to copy another investor’s holdings automatically, noting that an institution’s cost of capital, goals, and investment horizon may differ from an individual’s.
• He also named Berkshire Hathaway (BRK.A/BRK.B) and described its holdings as examples of Buffett’s investments, while emphasizing that 13F positions alone are not a personalized investment plan.

Takeaways

• The speaker presented 13F filings as a source of research ideas, not as a stand-alone buy signal.
• A practical takeaway from the discussion is to investigate why a fund owns a stock and whether that thesis fits one’s own objectives and risk tolerance.